Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | GALR1 | P47211 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096355 | 0.93 | TP53 (0.51) | TP53POLBHPGDCYP4F2CYP4A11 | |
| SCHEMBL13830587 | 0.86 | TP53 (0.50) | TP53POLBHPGDCYP4F2CYP4A11 | |
| SCHEMBL13830820 | 0.84 | CYP4F2 (0.51) | TP53POLBHPGDMEP1BCYP4F2 | |
| SCHEMBL4883544 | 0.81 | SMN1; SMN2 (0.49) | TP53POLBHPGD | |
| SCHEMBL29617015 | 0.81 | TP53 (0.62) | TP53POLBHPGDCYP4F2CYP4A11 | |
| SCHEMBL29677953 | 0.81 | MAPT (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3947571 | 0.81 | POLB (0.54) | TP53POLBHPGDCYP4F2CYP4A11 | |
| SCHEMBL245137 | 0.79 | KDM4E (0.65) | MEP1BCYP4F2CYP4A11CA12CA1 | |
| SCHEMBL29627840 | 0.79 | KDM4E (0.65) | MEP1BCYP4F2CYP4A11CA12CA1 | |
| SCHEMBL4193217 | 0.79 | TP53 (0.61) | TP53POLBHPGDCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083426-A1 | NON-BENZENOID AROMATIC SYSTEMS FOR IMAGING, MONITORING AND THERAPY | MEDIBEACON INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-9226980-B2 | Azulene and azaazulene systems for imaging, monitoring and therapy | MEDIBEACON INC. (US) | 2016-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083426-A1 | NON-BENZENOID AROMATIC SYSTEMS FOR IMAGING, MONITORING AND THERAPY | PAH, AHR, ALK | TP53 215/4885POLB 3774/4885HPGD 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.